📰 Pharmaceutical Intelligence News
Pharmaceutical Intelligence News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Pharmaceutical Intelligence. Real-time updates on events, politics, business and more.
February 20, 2024
Top 20 global biopharmaceutical companies report 1.6% market capitalization growth to $3.67 trillion in 2023, reveals GlobalData
February 19, 2024
VIS-954 is under clinical development by Visterra and currently in Phase I for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis).
February 9, 2024
Botensilimab is under clinical development by Agenus and currently in Phase I for Cervical Cancer.
February 9, 2024
Zalifrelimab is under clinical development by Agenus and currently in Phase II for Cervical Cancer.
February 9, 2024
Botensilimab is under clinical development by Agenus and currently in Phase I for Ovarian Cancer.
February 8, 2024
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Metastatic Colorectal Cancer.
February 8, 2024
Tisotumab vedotin is under clinical development by Genmab and currently in Phase II for Bladder Cancer.
February 8, 2024
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Endometrial Cancer.
February 8, 2024
Sirexatamab is under clinical development by Leap Therapeutics and currently in Phase II for Hepatocellular Carcinoma.
December 21, 2023
Entrectinib is under clinical development by F. Hoffmann-La Roche and currently in Phase II for Metastatic Uveal Melanoma.